| Similar Articles |
|---|
 |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.   |
The Motley Fool
March 3, 2009
Brian Orelli |
A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals. |
The Motley Fool
August 3, 2009
Brian Orelli |
The Roller-Coaster Stock That Keeps on Giving Savient's gout treatment isn't approved just yet. |
The Motley Fool
November 21, 2008
Brian Orelli |
The Comeback of the Century? AstraZeneca is trying to revive Iressa. |
The Motley Fool
December 20, 2004
Charly Travers |
More Trouble at Big Pharma AstraZeneca's lung cancer drug is not as effective as once hoped. |
The Motley Fool
October 2, 2008
Brian Orelli |
Will Lilly Buy ImClone's Troubles? Eli Lilly is reportedly ImClone's mystery suitor. Would it be a good deal? |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
March 15, 2010
Brian Orelli |
FDA Says "No Way!" Market Says "Yeah, Baby!" You can have it both ways. The Food and Drug Administration's response wasn't exactly what investors in Amylin Pharmaceuticals, Eli Lilly, and Alkermes were looking for, but they'll take it. |
The Motley Fool
December 14, 2010
Brian Orelli |
Another Mishap for a Drugmaker That Can't Afford It Eli Lilly puts cancer drug tasisulam on a clinical hold. |
The Motley Fool
July 6, 2009
Brian Orelli |
Lilly Shows Us How It's Done The company announces that the Food and Drug Administration had expanded the approval of its cancer drug, Alimta, to include maintenance therapy for nonsquamous, non-small cell lung cancer. |
The Motley Fool
June 4, 2008
Brian Lawler |
Erbitux's Deceptively Disappointing Results Poorly received lead-drug data batters ImClone shares. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
October 7, 2008
Brian Orelli |
Eli Lilly's Risky Gamble Eli Lilly is desperate, and the high acquisition price of ImClone shows it. |
The Motley Fool
November 29, 2011
Brian Orelli |
Winners and Losers of Roche's Avastin Woes What the FDA giveth, the FDA can taketh away. |
The Motley Fool
November 19, 2004
Charly Travers |
A New Drug for Lung Cancer Genentech and OSI's launch of Tarceva brings a new choice in the treatment of lung cancer. |
The Motley Fool
December 12, 2008
Brian Orelli |
A Long-Term Play for Your Port Long-term prospects look better than the near term ones for Eli Lilly and its investors. |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
The Motley Fool
June 26, 2009
Brian Orelli |
Looking for a Sliver of the Me-Too Pie Another diabetes drug is close to hitting the market. |
The Motley Fool
April 27, 2004
Alyce Lomax |
Imagining ImClone It's been hard to ignore the lure of cancer drugs over the last several days. Today, ImClone shares leapt after the company reported stellar first-quarter profits, boosted by its launch of colon cancer drug Erbitux. |
The Motley Fool
November 18, 2008
Brian Orelli |
Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February. |
The Motley Fool
January 29, 2009
Brian Orelli |
Lilly's in Need of a Pep Pill Eli Lilly's quarterly earnings report was pretty boring. Some drugs were up and others were down -- the end result was flat sales. |
The Motley Fool
December 9, 2008
Brian Orelli |
FDA Dashes Amylin Investors' Hopes Shareholders are still waiting to hear how much longer it'll be before Amylin and Eli Lilly can submit the marketing application for the once-weekly version of diabetes drug Byetta. |
The Motley Fool
January 31, 2008
Brian Lawler |
A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
The Motley Fool
December 12, 2008
Brian Orelli |
Amylin Gets Some FDA Love Amylin's once-weekly diabetes drug Byetta gets a green light from the FDA. |
The Motley Fool
February 10, 2009
Brian Orelli |
Roses and Candy From the FDA? Some drugmakers expect the FDA to bestow its kiss of approval this month. Read on to see who. |
The Motley Fool
October 20, 2010
Brian Orelli |
There Are No Safe Biotech Investments Amylin Pharmaceuticals and its partners, Eli Lilly and Alkermes, announced yesterday evening that the Food and Drug Administration had asked for more data before approving its once-weekly diabetes drug Bydureon. |
The Motley Fool
May 16, 2011
Brian Orelli |
Diabetes Drug Duo Duels It Out in Court Amylin sticks up to partner Eli Lilly. |
The Motley Fool
January 13, 2011
Brian Orelli |
FDA Panel Gives Eli Lilly Indigestion Eli Lilly's new acquisition causes a tummy ache. |
The Motley Fool
April 26, 2004
Alyce Lomax |
Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug. |
The Motley Fool
September 28, 2009
Brian Orelli |
Here We Go Again With Possible Side Effects The FDA says it has received 88 reports of pancreatitis in patients taking Merck's Januvia and Janumet. |
The Motley Fool
February 25, 2008
Brian Lawler |
A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer. |
The Motley Fool
April 19, 2011
Brian Orelli |
See You on the Other Side of the Cliff Lilly beats, but there's still a lot of unknowns. Can the company continue the trend through the patent cliff? |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
July 8, 2011
Brian Orelli |
Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues. |
The Motley Fool
October 21, 2010
Brian Orelli |
Nice Earnings, Eli Lilly, but ... Eli Lilly trounced analysts' earnings estimates today, but investors sighed -- and for good reason. |
The Motley Fool
July 23, 2010
Brian Orelli |
Eli Lilly Looks Great Today, but I'm Concerned About Tomorrow Eli Lilly is firing on all cylinders, but is there a blowout in its future? |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
The Motley Fool
October 22, 2010
Brian Orelli |
No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further. |
The Motley Fool
March 27, 2009
Brian Orelli |
The Skinny on a Triple-Decker Update Amylin's public relations department might need to go on a diet. |
The Motley Fool
April 21, 2011
Brian Orelli |
Who's Next? 5 Potential Biotech Takeover Targets Exelixis has reportedly hired Goldman Sachs to shop the development-stage drugmaker around to the highest bidder. With an asset like XL184, there should be someone interested. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
The Motley Fool
November 9, 2011
Brian Orelli |
Byetta Breakup! Buying Opportunity? We all saw this coming. Amylin Pharmaceuticals and Eli Lilly decided staying together for the kids just wasn't worth it |
The Motley Fool
February 4, 2009
Brian Orelli |
Not If, but When, for Lilly At least Lilly now knows that it's just a matter of time until the anti-clotting agent wins FDA approval. |
The Motley Fool
July 22, 2010
Brian Orelli |
It's All About the Future for Amylin Its second quarter stank, but there's a lot up ahead. |
